Clinical trials recruiting in Turin, Italy

Phase breakdown

Conditions recruiting in Turin, Italy

Recruiting trials in Turin, Italy

• A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
  NCT06747949 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
  NCT06570798 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
  NCT06226883 · Phase: Phase 2 · Ages: 18 Years to 85 Years · Sex: All (male and female)
• A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
  NCT05646862 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
  NCT05774951 · Phase: Phase 3 · Ages: 18 Years to 130 Years · Sex: All (male and female)
• A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
  NCT07012395 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study to Assess the Effectiveness of Second-Line Therapy of Upadacitinib and Risankizumab in Adult Participants With Crohn's Disease in a Real-World Setting
  NCT07073079 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
  NCT06819878 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
  NCT06241118 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
  NCT06430801 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female)
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
  NCT06979336 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
  NCT06867094 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
  NCT07184931 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female)
• CMP-MYTHiC Trial and Registry - CardioMyoPathy With MYocarditis THerapy With Colchicine
  NCT06158698 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes
  NCT05633810 · Phase: Phase 3 · Ages: 55 Years to 80 Years · Sex: All (male and female)
• Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
  NCT07087054 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Cera™ Vascular Plug System Post-Market Clinical Follow-Up
  NCT06099015 · Phase: Not specified · Ages: 18 Years to 85 Years · Sex: All (male and female)
• EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
  NCT06531824 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
  NCT05714085 · Phase: Phase 2, Phase 3 · Ages: 29 Days to 17 Years · Sex: All (male and female)
• Global Registry and Natural History Study for Mitochondrial Disorders
  NCT05554835 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female)
• PRESERFLO™ MicroShunt XI Observational PMCF Study With no Control Group
  NCT07235592 · Phase: Not specified · Ages: 18 Years to 85 Years · Sex: All (male and female)
• Predictors and Process Moderators of EMDR Therapy for Depressive Symptoms
  NCT07033741 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Prevention ICONA Dedicated Ensemble
  NCT07186244 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants With Advanced Parkinson Disease
  NCT06965374 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Remote ECG Monitoring Post TAVI
  NCT07521800 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• SILibinin in NSCLC and BC Patients With Single Brain METastasis (SILMET)
  NCT05689619 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 70 Years · Sex: All (male and female)
• Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
  NCT06548542 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Study of the Role of Genetic Modifiers in Hemoglobinopathies
  NCT05799118 · Phase: Not specified · Ages: 2 Years and older · Sex: All (male and female)
• The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
  NCT05973786 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
  NCT05973851 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
  NCT05958875 · Phase: Phase 4 · Ages: 18 Years to 70 Years · Sex: All (male and female)
• The European NAFLD Registry
  NCT04442334 · Phase: Not specified · Ages: 18 Years to 100 Years · Sex: All (male and female)
• The FOCUS-ADHF Registry
  NCT06726109 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female)
• Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
  NCT06526195 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Turin, Italy?

34 recruiting trials have at least one study site in Turin, Italy.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.